Ralph Minter

Ralph Minter is Chief Scientific Officer at Alchemab Therapeutics and leads the antibody discovery efforts, in Neuroscience and other areas. Prior to joining Alchemab, Ralph was Senior Director in Antibody Discovery and Protein Engineering at AstraZeneca where he led discovery teams and developed candidate drugs across multiple disease areas. Before joining AstraZeneca, he was part of Cambridge Antibody Technology (CAT), which later became MedImmune. In addition to antibody discovery, Ralph has worked extensively on phenotypic, or target-agnostic, antibody screening which has yielded many novel therapeutic targets, some of which are now being tested in clinical trials. Ralph earned his PhD in Immunology from Durham University and a BSc in Pathology and Microbiology from Bristol University.